Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Gastroenterology - Drug Trials For Money - Paid Clinical Trials

Gastroenterology

  • Home
  • Gastroenterology
Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
Narrow Band Imaging for Gastric Neoplasia
Conditions:   Gastric Cancer;   Gastric Metaplasia;   Gastric Dysplasia
Interventions:   Procedure: White light biopsy;   Procedure: Protocolled;   Procedure: Narrow Band Imaging Guided Biopsy
Sponsors:   University of Southern California;   Universidade do Porto
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 16, 2022 / by / in
Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample
Conditions:   Breast Cancer;   Stomach Neoplasms;   Salivary Gland Neoplasms;   Thyroid Cancer
Intervention:  
Sponsor:   Stanford University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 15, 2022 / by / in
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Condition:   Solid Tumors With PTCH1 Loss-of-function Mutations
Intervention:   Drug: ENV-101 (taladegib)
Sponsor:   Endeavor Biomedicines, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 15, 2022 / by / in
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Conditions:   Metastatic Esophageal;   Gastric Cancer;   Metastatic Head and Neck Carcinoma;   Metastatic Hepatocellular Carcinoma;   Metastatic HPV Related Solid Tumors;   Metastatic Ovarian Carcinoma;   Metastatic Soft Tissue Sarcoma;   Metastatic Uveal Melanoma
Interventions:   Drug: LVGN3616 + LVGN6051 + Nab-Paclitaxel;   Drug: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide;   Drug: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel;   Drug: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Sponsors:   M.D. Anderson Cancer Center;   Lyvgen Biopharma Holdings Limited
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 9, 2022 / by / in
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Conditions:   Oesophageal Squamous Cell Carcinoma;   Gastric Cancer;   Hepatocellular Carcinoma;   Colorectal Cancer;   Oseophageal Adenocarcinoma
Interventions:   Drug: THOR-707;   Drug: Pembrolizumab;   Drug: Cetuximab
Sponsors:   Sanofi;   Merck Sharp & Dohme LLC
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 28, 2022 / by / in
PillSense System for Detecting UGI Bleed
Conditions:   UGI Bleed;   Upper Gastrointestinal Bleeding;   Upper Gastrointestinal Bleed
Intervention:   Diagnostic Test: PillSense
Sponsors:   EnteraSense Limited;   Databean
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 24, 2022 / by / in
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Conditions:   Advanced Solid Tumor;   Gynecologic Cancer;   Breast Cancer;   Colorectal Cancer;   Gastric Adenocarcinoma;   Lung Adenocarcinoma;   Pancreatic Cancer;   Head and Neck Cancer
Interventions:   Drug: PY159 Single agent dose level 1;   Drug: PY159 Single agent dose level 2;   Drug: PY159 Single agent dose level 3;   Drug: PY159 Single agent dose level 4;   Drug: PY159 Single agent dose level 5;   Drug: PY159 Single agent dose level 6;   Drug: PY159 Single agent dose level 7;   Drug: PY159/Pembrolizumab Combination dose level 1;   Drug: PY159/Pembrolizumab Combination dose level 2;   Drug: PY159/Pembrolizumab Combination dose level 3;   Drug: PY159/Pembrolizumab Combination dose level 4;   Drug: PY159 Single agent dose expansion cohort;   Drug: PY159/Pembrolizumab Combination dose expansion cohort 1;   Drug: PY159/Pembrolizumab Combination dose expansion cohort 2;   Drug: PY159/Pembrolizumab Combination dose expansion cohort 3;   Drug: PY159/Pembrolizumab Combination dose expansion cohort 4;   Drug: PY159/Pembrolizumab Combination dose expansion cohort 5;   Drug: PY159/Pembrolizumab Combination dose expansion cohort 6
Sponsors:   Pionyr Immunotherapeutics Inc.;   Gilead Sciences
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 20, 2022 / by / in
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
Conditions:   Advanced Cancer;   Gastric Cancer;   Breast Cancer;   Pancreatic Cancer;   Prostate Cancer Metastatic;   Colo-rectal Cancer;   Solid Tumor;   Solid Carcinoma;   Solid Carcinoma of Stomach;   Cancer of Stomach;   Lymphoma;   Sarcoma;   Cutaneous T Cell Lymphoma;   Head and Neck Squamous Cell Carcinoma;   Basal Cell Carcinoma;   Cutaneous T-cell Lymphoma;   Cutaneous Squamous Cell Carcinoma
Interventions:   Drug: GZ17-6.02;   Drug: Capecitabine
Sponsors:   Genzada Pharmaceuticals USA, Inc.;   Translational Drug Development
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 19, 2022 / by / in
Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome
Condition:   Enteric Hyperoxaluria
Interventions:   Drug: SYNB8802v1;   Other: Placebo
Sponsor:   Synlogic
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 18, 2022 / by / in
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
Conditions:   Gastrostomy;   Gastric;   GastroEsophageal Cancer
Interventions:   Other: Standard of Care;   Other: Control Group
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 17, 2022 / by / in